Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOB | P04114 | 16/20 | 0.67 |
| ▸ | MTTP | P55157 | 15/20 | 0.67 |
| ▸ | SMO | Q99835 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13591660 | 0.88 | MTTP (0.78) | APOBMTTPSMO | |
| SCHEMBL10265197 | 0.80 | APOB (1.00) | APOBMTTPSMO | |
| SCHEMBL13591653 | 0.80 | APOB (0.88) | APOBMTTPSMO | |
| SCHEMBL13591630 | 0.78 | APOB (0.79) | APOBMTTPSMO | |
| SCHEMBL7760803 | 0.75 | APOB (0.76) | APOBMTTPSMO | |
| SCHEMBL7760794 | 0.75 | APOB (0.76) | APOBMTTPSMO | |
| SCHEMBL13591657 | 0.75 | MTTP (1.00) | APOBMTTPSMO | |
| SCHEMBL8208303 | 0.74 | APOB (0.62) | APOBMTTPSMOKDM4ELMNA | |
| SCHEMBL13591659 | 0.74 | MTTP (1.00) | APOBMTTPSMO | |
| SCHEMBL7761722 | 0.73 | APOB (0.76) | APOBMTTPSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306149-A1 | USE OF BIARYLCARBOXAMIES IN THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20090306149-A1 | USE OF BIARYLCARBOXAMIES IN THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306149-A1 | USE OF BIARYLCARBOXAMIES IN THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | GLI1, SHH, GLI2 | APOB 4403/4885MTTP 3269/4885SMO 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.